Dr. Paolo Gandellini’s scientific interests have been mainly focused on the validation of innovative therapeutic targets. Specifically, he acquired a good expertise in the design of third-generation antisense oligomers and small interfering RNAs, as well as in the development of strategies for their intracellular delivery (i.e. peptide nucleic acids conjugated to internalizing peptides or delivered to cells through photochemical internalization), mainly for the inhibition of cancer cell survival factors (i.e., telomerase) for research and therapeutic purposes. During his PhD, his scientific interests have been extended to the understanding of the role of microRNAs in the pathogenesis of human cancer, with the aim to identify and validate novel biomarkers and therapeutic targets. In this context, he acquired expertise in analyzing microRNA expression in cell lines and tissues, using standard molecular techniques and microarrays. He also developed skills in microRNA target prediction and functional validation in experimental models, with a specific interest in identifying microRNAs involved in the development and progression of prostate cancer. Currently, he is senior Postdoctoral fellow at Molecular Pharmacology Unit, Dept. Experimental Oncology and Molecular Medicine - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy).
Biography Updated on 23 February 2013